Key Players
Competitive Landscape
Four business models define the antiparasitic chemicals field: global animal-health groups, veterinary-channel specialists, livestock deworming manufacturers and regional companion-animal brands. Chemistry alone does not determine repeat use, so registered parasite breadth and administration fit separate these business models.
Portfolio investment shifted toward longer protection and geographic expansion in 2025. Virbac began offering an eight-month antiparasitic collar in France during August 2025. Petmedica launched Atrevia 360° in Guatemala with Monteco during October 2025. Veterinary clinics now compare treatment interval and parasite breadth alongside channel availability.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| August 2026: Zoetis received FDA emergency authorization for Simparica Trio against New World screwworm. | Outbreak planning pushes veterinarians toward treatment options that fit familiar monthly preventive routines. | Emergency authorizations are extending known brands into outbreak-specific indications. | Clinic-adopted brands can earn response demand without requiring a new administration routine. |
| April 2026: Norbrook launched Defendazole fenbendazole drench in the United States. | Cattle and goat producers need additional deworming choices for common internal parasites. | FDA-approved bioequivalent drenches are widening generic competition within livestock anthelmintic routes. | Farm distribution gives bioequivalent drenches a route into existing deworming protocols. |
| February 2026: Elanco secured APVMA registration for Advocate Ultra Chew in Australia. | Dog owners increasingly prefer one monthly administration covering internal and external parasites. | Country-specific registrations are expanding broad-spectrum endectocides into additional veterinary markets. | Clinic brands can extend revenue after a registration opens a new national treatment route. |
Vetoquinol and Phibro Animal Health compete outside the mapped developments through companion-animal deworming portfolios and food-animal medicated-feed routes.
Source: Future Market Insights, Antiparasitic Chemicals Market and Animal Parasiticides Market Reports, 2026-2036.
The reviewed companies span oral chews and topical products plus injectables and livestock drenches for companion-animal clinics and food-animal systems.
Who leads the antiparasitic chemicals market?
Elanco, Zoetis, MSD Animal Health and Boehringer Ingelheim hold the broadest verified multi-species positions among the companies reviewed here.
Which suppliers have documented qualification or quality approvals?
Elanco, Zoetis, MSD Animal Health and Boehringer Ingelheim each hold 2026 regulator approvals or authorizations represented in this section.
Which companies provide broad-spectrum companion-animal products?
Elanco, Zoetis, MSD Animal Health, Boehringer Ingelheim, Virbac, Petmedica and SAVAVET provide multi-parasite companion-animal products in the reviewed evidence.
Which suppliers serve North America and Europe?
Elanco, Zoetis, MSD Animal Health and Boehringer Ingelheim serve both North America and Europe, while Virbac and Norbrook also maintain documented operations in both regions.
Representative Company Overview
| Company | Positioning | Verified Development |
|---|---|---|
| Elanco | Global companion-animal and livestock parasiticide group | In February 2026, APVMA registered Advocate Ultra Chew for dogs in Australia. |
| Zoetis | Global companion-animal and livestock parasiticide group | In August 2026, FDA authorized Simparica Trio for New World screwworm treatment in dogs. |
| MSD Animal Health | Global veterinary company with extended-duration parasiticide programs | In March 2026, BRAVECTO QUANTUM received expanded USA tick-control claims. |
| Boehringer Ingelheim | Global companion-animal parasiticide group with oral and topical platforms | In January 2026, FDA approved a Gulf Coast tick indication for NexGard PLUS. |
| Virbac | Veterinary-channel specialist with companion and farm-animal antiparasitic ranges | In August 2025, Virbac introduced a long-duration antiparasitic collar in France. |
| Norbrook | Livestock pharmaceutical manufacturer with deworming and injectable routes | In April 2026, Norbrook launched Defendazole fenbendazole drench in the United States. |
| Petmedica | Regional companion-animal brand at the edge of the broader market scope | In October 2025, Petmedica launched Atrevia 360° in Guatemala with Monteco. |
| SAVAVET | Companion-animal pharmaceutical company at the edge of the broader market scope | In April 2025, SAVAVET launched Nulura fluralaner chewable tablets at its annual sales conference. |
Research Methodology
The companies mapped here illustrate the market structure rather than an exhaustive ranking. Inclusion requires current, verifiable evidence that a company supplies antiparasitic veterinary chemicals or formulations within the defined market scope. Evidence comes from regulatory approvals, third-party certifications, company announcements, product documentation, and public filings. Capabilities are attributed to the stated parasiticide product family or veterinary treatment route rather than generalised across broader corporate portfolios. Market-share estimates remain proprietary FMI assessments for the forecast period.
